Decoding secret role of mesenchymal stem cells in regulating cancer stem cells and drug resistance

Area of Science:

• Oncology
• Cancer Biology
• Stem Cell Research

Background:

• Drug resistance, particularly mediated by efflux transporters like P-gp/ABCB1, significantly impedes effective cancer chemotherapy.
• Despite advancements in efflux transporter inhibitors, complete inhibition remains elusive, highlighting the need for alternative strategies.
• Cancer stem cells (CSCs) contribute to tumor recurrence and are inherently resistant to conventional treatments due to their dormant state.

Purpose of the Study:

• To review the regulatory role of Mesenchymal stem cells (MSCs) in the Tumor Microenvironment (TME).
• To elucidate the mechanisms by which MSCs influence both CSCs and efflux transporter activity.
• To propose a novel therapeutic strategy targeting MSCs for overcoming chemoresistance and CSC-mediated recurrence.

Main Methods:

• Literature review focusing on the interaction between MSCs, CSCs, and efflux transporters within the TME.
• Analysis of existing research on the role of the TME in cancer drug resistance.
• Synthesis of findings to propose a new therapeutic paradigm.

Main Results:

• Mesenchymal stem cells (MSCs) are identified as key regulators within the Tumor Microenvironment (TME).
• MSCs influence the behavior of both cancer stem cells (CSCs) and the expression/activity of efflux transporters.
• The interplay between MSCs, CSCs, and efflux transporters presents a critical target for overcoming therapeutic resistance.

Conclusions:

• Targeting Mesenchymal stem cells (MSCs) offers a promising new avenue for combating cancer drug resistance.
• Understanding the MSC-mediated regulation of CSCs and efflux transporters is crucial for developing effective cancer therapies.
• A therapeutic approach focused on modulating MSCs could potentially address both treatment resistance and cancer recurrence.